Mangoceuticals, Inc. Common Stock (MGRX) — Cash Flow-to-Debt Ratio
Mangoceuticals, Inc. Common Stock (MGRX) has a Cash Flow-to-Debt Ratio of -1.54x as of September 2025, meaning its operating cash flow of $-1.24 Million could theoretically repay -2% of its total liabilities ($804.27K) in one year. See working capital position of Mangoceuticals, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mangoceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2024)
Historical debt coverage capacity for Mangoceuticals, Inc. Common Stock across 4 annual periods. Also explore Mangoceuticals, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mangoceuticals, Inc. Common Stock (2021–2024)
Year-by-year debt coverage analysis for Mangoceuticals, Inc. Common Stock. For market capitalisation and broader financial context, see Mangoceuticals, Inc. Common Stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.41x | $-4.86 Million | $1.43 Million | ▲ +86.5% |
| 2023 | -25.35x | $-7.00 Million | $276.04K | ▼ -632.8% |
| 2022 | -3.46x | $-1.35 Million | $389.26K | ▼ -675.4% |
| 2021 | -0.45x | $-17.52K | $39.27K | — |